AstraZeneca Gets Revenue Boost From Cancer Drugs
AstraZeneca reported rises in revenue and core earnings for the first quarter, saying growing sales of its cancer and rare-disease drugs lifted results.
AstraZeneca beats expectations
- UK's biggest drugmakers see surprise profit bump, even as pharma grapples with U.S. policies CNBC —
- Astrazeneca tops expectations in the first quarter on strong cancer drug sales Associated Press —
- AstraZeneca posted stronger-than-expected profit and revenue on surging cancer drug sales Quartz —
- AstraZeneca makes surprise U-turn with £300m pharma investment The Guardian —
- Shot in the arm for GSK and AstraZeneca from cancer drug sales The Argus —